Article

Continuous versus cyclic menopause HRT: the regimen is about timing, not just ingredients

Continuous combined HRT supplies estrogen and progestogen together throughout a regimen; cyclic or sequential HRT changes the progestogen phase. That timing affects expected bleeding and adherence discussions, while the uterus and exact product still determine the safe plan.

3 min read Published Source checked

Continuous blue loop beside a segmented coral loop, both laid out as abstract timelines
Treomark original editorial illustration

Continuous versus cyclic menopause hormone therapy describes when the progestogen is given, not a contest between “strong” and “weak” hormones. In a continuous-combined regimen, estrogen and progestogen are supplied together throughout treatment. In a cyclic or sequential regimen, estrogen continues while the progestogen is introduced for a defined phase. For someone with a uterus, either plan must address endometrial protection; the planned bleeding pattern and the exact prescription should be explained before starting.123

A product label makes the distinction concrete

The U.S. CombiPatch label describes trials of both a continuous-combined regimen using the combined patch throughout and a continuous-sequential regimen that used an estradiol-only patch during one part of the cycle and CombiPatch during another. The label reports symptom and endometrial findings for those studied regimens, not a general instruction to assemble a patch calendar at home. The existence of two patterns shows why “I have a combined patch” and “I use a continuous combined regimen” are related but not identical statements.1

PatternWhat changes across the cycleBleeding discussion
Continuous combinedEstrogen and progestogen are supplied together throughout the prescribed plan.Aims toward no scheduled withdrawal bleed, but spotting can occur.
Cyclic or sequentialThe progestogen is used during a defined phase alongside ongoing estrogen.A planned withdrawal bleed may be expected.
Estradiol without a progestogen plan in someone with a uterusThe protective component is not documented.This is not simply a third lifestyle preference; endometrial risk needs review.

The British Menopause Society clinician tool describes sequential and continuous-combined patterns and their differing bleeding expectations. It is useful terminology, but its UK prescribing details should not be copied into a U.S. treatment schedule. The exact American product label and the treating clinician’s plan govern what a patient receives. The Menopause Society likewise notes that a uterus changes the need for progestogen with systemic estrogen.23

A planned bleed is not a free pass for every bleed

Regimen timing can make a recurring withdrawal bleed expected. It does not make all bleeding routine. Unfamiliar, heavy, persistent, or otherwise concerning bleeding should be reported according to the care team’s instructions and assessed in context. Our unscheduled-bleeding guide owns that later evaluation question. This page is about understanding the chosen regimen before it starts or changes, not diagnosing a bleeding episode.

The combination-versus-estradiol-only patch guide answers what hormones are inside a finished patch. This article asks when those hormones are present across a plan. A person can understand both without trying to construct a regimen themselves; a clinician must account for the indication, uterus status, timing since menopause, preferences, and product labeling.

Ask for a written map

The timing distinction is often lost when a patient receives separate prescriptions. A patch, gel, or tablet supplying estrogen may have one refill date, while a progestogen has another. A missing refill can unintentionally change the regimen even though the patient still thinks they are “on HRT.” Ask the clinician or pharmacist to list each product’s role and the intended pattern in one place. That is a medication-reconciliation safeguard, not a request for a self-directed schedule.13

There is also a language trap: “continuous estrogen” does not necessarily mean “continuous combined.” In a sequential plan, estrogen may be present throughout while the progestogen appears only in a defined phase. CombiPatch’s label explicitly describes a continuous-sequential study regimen with that structure. If a practice uses the shorthand “continuous HRT,” ask which hormone it means and whether a scheduled withdrawal bleed is anticipated. The answer should match the actual product record.1

“Is my plan continuous combined or cyclic? Which exact product supplies estrogen, which supplies progestogen, and what bleeding pattern should I expect? If the pattern differs, whom do I contact?” A written answer helps prevent a refill or substitution from silently changing the intended regimen. It also helps a new clinician understand what was actually used rather than infer from the word “HRT.”

Use Treomark’s hormone-therapy directory to compare ongoing-care access. The better choice is an individually justified, understandable plan—not whichever pattern a marketing page calls more natural or modern.

Sources

  1. National Library of Medicine DailyMed. COMBIPATCH estradiol/norethindrone acetate prescribing information. Exact U.S. product label compares continuous-combined and continuous-sequential study regimens and endometrial and bleeding outcomes. Accessed .
  2. British Menopause Society. Progestogens and endometrial protection: tool for clinicians. Professional explanation of sequential versus continuous-combined patterns; UK recommendations are context, not a U.S. prescription schedule. Accessed .
  3. The Menopause Society. Menopause Topics: Hormone Therapy. Systemic HRT, need for endometrial protection with a uterus, and individualized risk-benefit review. Accessed .
Built from the public records listed above. Spot an error? Report a correction